Publications Lene Uhrbom

Publications in DiVA

Publications in PubMed

Selected publications:

  1. Lu X, Maturi NP, Jarvius M, Yildirim I, Dang Y, Zhao L, Xie Y, Tan EJ, Xing P, Larsson R, Fryknäs M, Uhrbom*# L, Chen*# X. Cell-lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival. Nat Commun. 2022, 13(1):2236.
  2. Maturi NP, Tan E-J, Xie Y, Sundström A, Bergström T, Jiang Y, Uhrbom# L. A molecularly distinct subset of glioblastoma requires serum-containing media to establish sustainable bona fide glioblastoma stem cell cultures. Glia. 2020, 68(6):1228-1240.
  3. Xie Y, Sundström A, Maturi NP, Tan EJ, Marinescu VD, Jarvius M, Tirfing M, Jin C, Chen L, Essand M, Swartling FJ, Nelander S, Jiang Y, Uhrbom# L. LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients. J Pathol. 2019, 247(2):228–240.
  4. Sreedharan S, Maturi NP, Xie Y, Sundström A, Jarvius M, Libard S, Alafuzoff I, Weishaupt H, Fryknäs M, Larsson R, Swartling* FJ and Uhrbom*# L. Mouse models of pediatric supratentorial high-grade glioma reveal how cell of origin influences tumor development and phenotype. Cancer Res. 2017, 77(3):802–812.
  5. Jiang Y, Marinescu VD, Xie Y, Jarvius M, Haglund C, Maturi, NP, Olofsson S, Lindberg N, Olofsson T, Leijonmarck C, Hesselager G, Alafuzoff I, Fryknäs M, Larsson R, Nelander# S, and Uhrbom# L. Glioblastoma cell malignancy and drug sensititvity are affected by the cell of origin. Cell Rep. 2017, 18(4):977–990.
  6. Xie Y, Bergström T, Jiang Y, Johansson P, Marinescu VD, Lindberg N, Segerman A, Wicher G, Niklasson M, Baskaran S, Sreedharan S, Everlien I, Kastemar M, Hermansson A, Elfineh L, Libard S, Holland EC, Hesselager G, Alafuzoff I, Westermark* B, Nelander*# S, Forsberg-Nilsson* K, and Uhrbom*# L. The human glioblastoma cell culture resource: validated cell models representing all molecular subtypes. EBioMedicine. 2015, 2(10):1351–1363.
  7. Lindberg N, Jiang Y, Xie Y, Bolouri H, Kastemar M, Olofsson T, Holland EC, and Uhrbom# L. Oncogenic signaling is dominant to cell of origin and dictates astrocytic or oligodendroglial tumor development from oligodendrocyte precursor cells. J Neurosci. 2014, 34(44):14644–14651.
  8. Lindberg N, Kastemar M, Olofsson T, Smits A, and Uhrbom# L. Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma. Oncogene. 2009, 28(23):2266–2275.
  9. Tchougounova E, Kastemar M, Bråsäter D, Holland EC, Westermark B, Uhrbom# L. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene. 2007, 26(43):6289–6296.
  10. Uhrbom1 L,  Nerio1 E, and Holland EC. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med. 2004, 10(11):1257–1260.

1co-first, *co-senior, #corresponding author

Last modified: 2023-02-01